drugset / Trial / NCT00680680

Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker

NCT00680680

Completed 20 enrolled Franklin D. Gaylis, MD Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter. Following treatment with an Alpha Blocker alone.

Timeline

Start
2004-05
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutasteride Small molecule 0.5 mg